P-1214. In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
Abstract
Abstract Background Tebipenem pivoxil hydrobromide (formerly SPR994) is in clinical development as potentially the first oral broad-spectrum carbapenem agent in the US for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). This study reports on the in vitro activity of tebipenem and comparator agents tested against Enterobacterales isolates recovered from UTI and bloodstream infections (BSI) in the US. Methods Between 2023 and 2024, 7,694 Enterobacterales clinical isolates were collected from 72 medical centers in the US and UK. These included 73.5% (5,654) from UTI (54.8% (3101) outpatients; 28.7% (1624) inpatients, including 11% (179) hospital-acquired infections) and 26.5% (2,040) from BSI (22.4% (456) outpatients; 67% (1366) inpatients, including 19% (261) hospital-acquired infections). Isolates were tested for susceptibility by CLSI reference broth microdilution method. MIC results for comparator agents were interpreted using the most recent CLSI M100 (2025) breakpoint criteria. Results Tebipenem MIC50 and MIC90 values against all 7,694 Enterobacterales isolates were 0.015 μg/mL and 0.06 μg/mL, respectively (UTI and BSI specific results are shown in the Table). Similar MIC50/90 values were obtained for ertapenem (MIC50/90, ≤0.008/0.06 μg/mL), imipenem (MIC50/90, ≤0.12/1 μg/mL), and meropenem (MIC50/90, 0.03/0.06 μg/mL). The susceptibility rates for recommended comparator agents were below 89% for levofloxacin (81.5%, MIC50/90,…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.